3.0.0
6832
2022-12-30T04:33:55Z
2022-12-30T04:33:55Z
House
HR
2022-02-25
117
[Congressional Record Volume 168, Number 35 (Friday, February 25, 2022)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. CLOUD:H.R. 6832.Congress has the power to enact this legislation pursuantto the following:Congress has the power to enact this legislation pursuantto Article 1, Section 8 of the Constitution.[Page H1147]
- hsif00
Energy and Commerce Committee
House
Standing
  - hsif14
Health Subcommittee
    - Referred to
2022-02-28T19:23:47Z
  - Referred to
2022-02-25T17:33:10Z
- hsba00
Financial Services Committee
House
Standing
  - Referred to
2022-02-25T17:33:15Z

- A bill to amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
117
3440
S
2022-01-04
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
  - Identical bill
CRS
- 2022-02-28
  - hsif14
Health Subcommittee
1
House committee actions
Referred to the Subcommittee on Health.
Committee
- 2022-02-25
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
IntroReferral
H11100
2
House floor actions
  - hsba00
Financial Services Committee
- 2022-02-25
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
IntroReferral
H11100
2
House floor actions
  - hsif00
Energy and Commerce Committee
- 2022-02-25
Introduced in House
IntroReferral
Intro-H
9
Library of Congress
- 2022-02-25
Introduced in House
IntroReferral
1000
9
Library of Congress
- C001115
Rep. Cloud, Michael [R-TX-27]
Michael
Cloud
R
TX
27
N
- W000806
Rep. Webster, Daniel [R-FL-11]
Daniel
Webster
R
FL
11
2022-02-25
True
- B001302
Rep. Biggs, Andy [R-AZ-5]
Andy
Biggs
R
AZ
5
2022-02-25
True
- M001211
Rep. Miller, Mary E. [R-IL-15]
Mary
Miller
R
IL
E.
15
2022-02-25
True
- T000165
Rep. Tiffany, Thomas P. [R-WI-7]
Thomas
Tiffany
R
WI
P.
7
2022-02-25
True
- D000032
Rep. Donalds, Byron [R-FL-19]
Byron
Donalds
R
FL
19
2022-02-25
True
- B001274
Rep. Brooks, Mo [R-AL-5]
Mo
Brooks
R
AL
5
2022-02-28
False
Health
- Cardiovascular and respiratory health
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Emergency medical services and trauma care
- Health care coverage and access
- Health programs administration and funding
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Intergovernmental relations
- Military procurement, research, weapons development
- Presidents and presidential powers, Vice Presidents
- Public contracts and procurement
- State and local government operations
Health
00
2022-02-25
Introduced in House
2022-06-06T16:00:52Z
This bill restricts various presidential and federal authorities related to the acquisition of supplies to combat COVID-19.
Specifically, the bill prohibits the President from exercising certain authorities under the Defense Production Act of 1950 to prioritize the performance of federal contracts or orders for COVID-19 supplies over the performance of state or territorial contracts or orders. In addition, states or territories may use federal COVID-19 relief funds for COVID-19 supplies that they had been unable to purchase because of prioritized performance of federal contracts or orders. (The Defense Production Act of 1950 confers upon the President a broad set of authorities to influence domestic industry in order to provide essential materials and goods needed for the national defense.)
Additionally, the Food and Drug Administration may not ration, limit, restrict access to, or otherwise control the quantity of a medical product authorized for use during an emergency, including by requiring products to be distributed through a state- or territorial-based system.

To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
- Display Title

To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
- Official Title as Introduced

To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
Introduced in House
IH
- Introduced in House
2022-02-25T05:00:00Z
  - https://www.govinfo.gov/content/pkg/BILLS-117hr6832ih/xml/BILLS-117hr6832ih.xml
2022-02-28
Referred to the Subcommittee on Health.
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
Congressional Research Service, Library of Congress
This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.